Principal Financial Group Inc. Has $309,000 Stake in Elanco Animal Health Incorporated (NYSE:ELAN)

Principal Financial Group Inc. decreased its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 18.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,525 shares of the company’s stock after selling 5,964 shares during the quarter. Principal Financial Group Inc.’s holdings in Elanco Animal Health were worth $309,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. DDD Partners LLC acquired a new stake in shares of Elanco Animal Health in the 4th quarter valued at about $5,974,000. Rhumbline Advisers increased its position in shares of Elanco Animal Health by 0.5% in the fourth quarter. Rhumbline Advisers now owns 481,438 shares of the company’s stock valued at $5,830,000 after acquiring an additional 2,209 shares during the last quarter. Blue Trust Inc. increased its position in shares of Elanco Animal Health by 47.7% in the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock valued at $71,000 after acquiring an additional 1,894 shares during the last quarter. MTM Investment Management LLC increased its position in shares of Elanco Animal Health by 9.3% in the fourth quarter. MTM Investment Management LLC now owns 14,168 shares of the company’s stock valued at $172,000 after acquiring an additional 1,200 shares during the last quarter. Finally, Van ECK Associates Corp increased its position in shares of Elanco Animal Health by 4.0% in the fourth quarter. Van ECK Associates Corp now owns 944,978 shares of the company’s stock valued at $11,444,000 after acquiring an additional 36,239 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ELAN. Morgan Stanley lowered their target price on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 26th. Leerink Partners began coverage on Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 target price on the stock. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Stifel Nicolaus lowered their target price on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, February 21st. Finally, Barclays reduced their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Elanco Animal Health presently has a consensus rating of “Hold” and a consensus target price of $15.17.

Elanco Animal Health Trading Up 2.7 %

Elanco Animal Health stock opened at $11.12 on Friday. Elanco Animal Health Incorporated has a 52 week low of $10.20 and a 52 week high of $18.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The stock has a market capitalization of $5.50 billion, a P/E ratio of 27.80, a PEG ratio of 2.50 and a beta of 1.44. The stock has a 50-day simple moving average of $11.64 and a 200 day simple moving average of $12.94.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the previous year, the business posted $0.08 EPS. The company’s revenue for the quarter was down 1.4% on a year-over-year basis. Analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.